Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking Therapeutics Offers An Obesity Drug for Healthy Adults
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 demonstrate at least 10% weight loss compared with 4% for placebo. The trial is conducted in 28 days. And those with the highest dose of 100 mg lost an average of 8.2% of body weight.
Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results
Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from clinical trials of its weight loss drugs.
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes.
Viking Therapeutics stock jumps after weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
Viking rises after 'competitive' efficacy, safety data from oral weight-loss drug
(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight with mild side effects in a small trial, data that analysts said compared favorably to some rivals in development.
Viking Therapeutics surges after presenting ‘promising’ obesity drug data
Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental
Viking Therapeutics Jumps On Latest Obesity Drug Data
Viking Therapeutics reported promising early results for its experimental obesity pill, with increased weight loss at higher doses. Viking stock jumped early Monday, but came well off premarket highs.
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations. Patients who received the higher dose 100 milligram version of the oral drug,
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Should you buy Viking Therapeutics (VKTX) after today’s spike?
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...
bovnews1d
A Pill for the Future: Viking Therapeutics (VKTX) Takes Center Stage in Obesity Solutions
As Viking Therapeutics continues to advance its clinical programs, the implications for patients and investors are substantial. The promising early results from VK2735 not only signify a potential ...
Barchart on MSN6d
Up 285% YTD, Is It Too Late to Buy This Biotech Stock?
Charting, Price Performance, News & Related Contracts.
SchaeffersResearch.com1d
Biotech Stock Reverses Gains Despite Obesity Pill Buzz
Viking Therapeutics (VKTX) stock is reversing gains despite earlier announcing strong results for its experimental obesity pill ...
bovnews5d
Why Viking Therapeutics Inc (VKTX) Stock is Currently 7.51% Above from Its 20-Day SMA?
On Wednesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $71.75 which represents a decrease of $-1.60 or -2.18% from the prior close of $73.35. The stock opened at $71 and ...